Product Description
Mechanisms of Action: EP2 Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | France | Greece | Hungary | India | Italy | Korea | Netherlands | Pakistan | Portugal | Switzerland | Taiwan | Thailand
Approved Indications: None
Known Adverse Events: None
Company: Atrium Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|